Pulmonary Arterial Hypertension (PAH) Market in United States, United Kingdom– Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

1. Executive Summary: Pulmonary Arterial Hypertension (PAH)
   • Global Market Outlook: Pulmonary Arterial Hypertension (PAH)
2. Competitive Intelligence Analysis: Pulmonary Arterial Hypertension (PAH)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Pulmonary Arterial Hypertension (PAH)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Pulmonary Arterial Hypertension (PAH)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Pulmonary Arterial Hypertension (PAH): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Pulmonary Arterial Hypertension (PAH): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Pulmonary Arterial Hypertension (PAH): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer

Pulmonary Arterial Hypertension Market – Report Overview

Pacific Business Consulting’s “Pulmonary Arterial Hypertension (PAH) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Pulmonary Arterial Hypertension (PAH), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The market size of Pulmonary Arterial Hypertension (PAH) across the 8 Major Markets (8MM) was estimated at US$4.3 billion in 2022, and it is projected to experience a compound annual growth rate (CAGR) exceeding 3.5% during the forecast period from 2023 to 2030. The United States contributed the largest share, accounting for approximately 80% of the total sales in the 8MM countries.

Existing primary treatments for Pulmonary Arterial Hypertension aim to widen the pulmonary vasculature, reducing pulmonary vascular resistance and subsequently enhancing right ventricular function, leading to improvements in functional capacity. The overarching treatment objective is to enhance survival, quality of life, exercise capacity, symptom relief, and clinical outcomes. Risk stratification tools are increasingly employed to guide therapy and optimize various aspects of patient care. Treatment recommendations consider factors such as World Health Organization Functional Class (WHO FC), exercise capacity, laboratory indices, and hemodynamic and echocardiographic variables to determine disease severity and tailor the intensity of therapy. The step-by-step management approach to PAH involves general supportive care initially and progresses to targeted pharmacological therapies.

Individuals with PAH who exhibit vasoreactivity during a right heart catheterization (RHC) are typically treated with calcium channel blockers (CCB) like nifedipine, diltiazem, and amlodipine. For those who either do not meet vasoreactivity criteria or show an inadequate response, treatment choices involve targeted monotherapy or combination therapies addressing the underlying pathophysiology of the disease. Notable drug classes in the PAH market include sGC Stimulators, Endothelin Receptor Antagonists, PDE5 Inhibitors, Nitric-Oxide Synthase Endothelial Activators, Prostacyclin Receptor Agonists, Tyrosine Kinase Inhibitors, and BMP 10 Inhibitors. Endothelin Receptor Antagonists dominated the Pulmonary Arterial Hypertension market in the United States.

Key players in the Pulmonary Arterial Hypertension market include Acceleron, Actelion, Aerovate Therapeutics, Bayer, CMP Pharma, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, and Liquidia Technologies.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Pulmonary Arterial Hypertension (PAH) market. It also delves into the analysis of present and prospective market competition within the global Pulmonary Arterial Hypertension (PAH) market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Pulmonary Arterial Hypertension (PAH) market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Pulmonary Arterial Hypertension (PAH) market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.